March 2012 Newsletter

March 20, 2012:

US IOL Procedures Climb 3.6 Percent in Q4-2011

In Q4-2011 US IOL procedure volume climbed a bit faster than recent trends have indicated, posting a 3.6 percent rise over procedure volume in Q4-2010.

March 20, 2012:

Toric IOL Demand Outpaces Demand for All Other Premium IOLs

While demand for toric IOLs has climbed sharply, outpacing that of other premium IOLs, the size of the astigmatic cataract patient population suggests a market opportunity barely tapped.

March 20, 2012:

Regeneron’s Eylea Threatens Lucentis Franchise

Regeneron’s Eylea entered the US market in late 2011 and has begun to reshape care for AMD patients and IVT injection regimens.

March 20, 2012:

Newer Implantable Devices will Boost Future Revenue Growth in the Retinal Surgical Device Market

We expect the global retinal surgical device market to grow at a CAGR of more than 7 percent over the next five years, in part driven by newer implantable devices for severe vision loss.

March 20, 2012:

Market for Presbyopia Surgeries Is Poised for Rapid Growth

Although the market is still in its infancy, we expect nearly a four-fold increase in the number of presbyopia-correcting surgeries by 2020.

March 20, 2012:

March 2012 News Briefs

This month's news includes the latest from Alimera Sciences, LensAR, Bausch + Lomb, NicOx, Thrombogenics and Avedro.

Social media